Fig. 4
From: Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies
Alu methylation analysis of MDS patients. a Alu methylation levels of the 7 MDS patients analyzed at diagnosis and after the cycles with AZA. For 3 MDS patients (cases#1–3), the methylation level was also analyzed after the progression to AML. b Box plot representation of Alu sequences methylation levels in relation to hypomethylating agents therapy. The percentage of methylated consensus Alu sequences was calculated as the ratio between the sum of the three values of positive droplets compared to HpaII (MH) and MspI (MM) diluted digestion-ligation mixtures. AZA, 5-azacytidine